Dear Editor, Since the first outbreak in late 2019, the RNA genome of SARS-CoV-2 has
been undergoing constant evolution. This is largely attributed to the viral polymerase that is …

Background: The rapid worldwide spread of the Omicron variant of SARS-CoV-2 has
unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved …

Dear Editor, Omicron (B. 1.1. 529), is a heavily mutated and highly contagious SARS-CoV-2
variant, which is currently causing large outbreaks in many countries. Protection provided by …

Variants of SARS-CoV-2 have become a major public health concern due to increased
transmissibility, and escape from natural immunity, vaccine protection, and monoclonal …

Dear Editor, Since the emergence of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) in 2019, the virus has continued to evolve resulting in new waves of infection …

Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …

The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
major antigen stimulating the host's protective immune response. Here we assessed the …

The recent emergence of the SARS-CoV-2 Omicron variant of concern (VOC), which
contains a heavily mutated spike protein capable of escaping preexisting immunity …

Dear Editor, As of December, 2021, more than 272 million people have been infected with
SARS-CoV-2. Multiple types of vaccines have been used to build herd immunity for the …

Molnupiravir has been the first oral antiviral authorized for COVID-19 outpatients, reporting
extraordinary sales and preserved in vitro efficacy against Omicron sublineages so far …